Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Precision BioSciences, Inc. (Nasdaq: DTIL) provides access to the company’s official regulatory disclosures as a clinical stage gene editing company. These documents offer detailed information on its ARCUS-based in vivo gene editing programs, financial condition, capital raising activities, and other material events relevant to shareholders and analysts.
Among the key filings are Current Reports on Form 8-K, which Precision uses to report significant developments. Examples include an 8-K describing an underwritten offering of common stock, pre-funded warrants, and warrants, with net proceeds intended to fund ongoing and planned research and development, working capital, and general corporate purposes. Other 8-Ks furnish press releases on clinical data from the ELIMINATE-B trial of PBGENE-HBV, updates on PBGENE-DMD, quarterly financial results, and executive employment arrangements.
Filings related to PBGENE-HBV summarize clinical findings such as dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), biopsy evidence of ARCUS-mediated viral DNA editing, and safety data across multiple cohorts. These reports help readers understand how Precision evaluates safety, efficacy, and dosing strategy for its hepatitis B program. Additional disclosures describe regulatory designations, trial expansion plans, and the structure of ongoing Phase 1/2a studies.
For capital markets activity, SEC filings detail the terms of equity offerings, including the number of shares and warrants issued, exercise prices, and intended use of proceeds. Exhibits to these filings may include underwriting agreements, warrant forms, and legal opinions on the validity of securities.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly grasp the implications of new 8-Ks and other reports. Real-time updates from EDGAR, combined with structured access to items such as clinical trial updates, financing transactions, and governance changes, make this page a focused resource for reviewing Precision BioSciences’ regulatory history and ongoing obligations.
Precision BioSciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held May 21, 2026. The Board asks shareholders to elect two Class I directors, ratify Deloitte & Touche LLP as auditor, approve say-on-pay, approve an amendment and restatement of the 2019 Incentive Award Plan to add 3,800,000 shares, approve an amendment to the Certificate of Incorporation to add officer exculpation under Delaware law, and approve an adjournment option to solicit additional proxies if needed.
The proxy materials are available at www.proxyvote.com and the meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/DTIL2026. Holders of record as of the March 25, 2026 record date may vote electronically, by telephone, by returning a signed proxy card, or online during the meeting.
Precision BioSciences is updating investors on PBGENE-DMD, its in vivo gene-editing program for Duchenne muscular dystrophy. The therapy uses a single AAV vector encoding two ARCUS nucleases to excise exons 45–55 of the dystrophin gene, aiming to restore near full-length, functional dystrophin for up to 60% of patients.
Preclinical DMD mouse data show increased dystrophin protein, up to about 85% dystrophin-positive myofibers, improved creatine kinase levels, and durable muscle force gains out to nine months, with supportive safety data in mice and non-human primates. The FDA granted US IND clearance for PBGENE-DMD in early Q1 2026, and the Phase 1/2 FUNCTION-DMD trial plans to test a 1 × 10¹⁴ vg/kg dose, targeting enrollment of 3–5 children in 2026 with initial multi-patient data expected by year end.
The company also highlights its HBV gene-editing program, additional 2026 data milestones across its pipeline, and reports approximately $137 million in cash, cash equivalents, and restricted cash as of year-end 2025, which it believes can support operations through multiple catalysts into 2028.
Precision BioSciences, Inc. is a clinical-stage gene editing company built around its proprietary ARCUS meganuclease platform, which aims to deliver precise DNA cuts with a small, single-component editor suitable for in vivo delivery.
The company is advancing two lead in vivo programs: PBGENE-HBV, a potentially curative treatment targeting hepatitis B cccDNA in the Phase 1/2a ELIMINATE-B trial, and PBGENE-DMD, an exon 45–55 excision approach for Duchenne muscular dystrophy with initial Phase 1/2 data expected by year end 2026. A third mitochondrial program, PBGENE-3243, is paused to prioritize these assets.
Precision highlights partnered programs such as iECURE’s OTC deficiency therapy ECUR-506, which has RMAT designation and early clinical response at the lowest dose, and out-licensing deals with Caribou, TG Therapeutics and Imugene. A 2022 collaboration with Novartis for hemoglobinopathies was terminated effective January 30, 2026, with all options and licenses reverting to Precision.
The filing underscores significant risks, including ongoing operating losses, substantial future funding needs, competition from other genome-editing technologies, regulatory and manufacturing complexity, and potential Nasdaq listing challenges. Precision reports a broad global patent estate around ARCUS, in vivo gene editing, and CAR T technologies, supported by foundational licenses from Duke University and cross-licensing with Cellectis.
Precision BioSciences reported a sharp swing to profitability in the fourth quarter of 2025 while advancing its in vivo gene editing pipeline. Q4 revenue rose to $34.2 million from $0.6 million a year earlier, driving net income of $20.1 million versus a prior net loss of $17.8 million.
For 2025, revenue was $34.3 million compared with $68.7 million in 2024, and the company posted a net loss of $45.7 million versus net income of $7.2 million, reflecting lower collaboration revenue. Cash, cash equivalents, and restricted cash were $137.2 million as of December 31, 2025, supported by a $75 million equity offering and milestone payments, and management expects this to fund operations through 2028. Clinically, PBGENE-HBV showed dose-dependent antiviral activity with repeat LNP dosing, PBGENE-DMD received FDA Fast Track and IND clearance for the Phase 1/2 FUNCTION-DMD trial, and partnered programs delivered regulatory milestones and additional data catalysts for 2026.
Precision BioSciences President and CEO Michael Amoroso reported a mix of RSU vesting and a tax-related share sale. On February 17, 2026, 67,797 Restricted Stock Units vested, with each RSU converting into one share of common stock. On February 18, 2026, he sold 20,559 common shares at $3.84 per share in an open-market transaction executed under a pre-arranged Rule 10b5-1 plan, solely to cover tax withholding and related fees from the RSU vesting. Following these transactions, he directly held 243,392 shares of common stock and 135,593 RSUs, which continue to vest in three substantially equal annual installments beginning February 17, 2026, contingent on continued service.
Precision Biosciences Chief Financial Officer John Alexander reported RSU vesting and related share transactions. On February 17, 2026, 27,584 Restricted Stock Units vested, each representing a right to receive one share of common stock, and were settled into 27,584 common shares at a stated price of $0.00 per share.
On February 18, 2026, he sold 8,149 common shares at $3.84 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. According to the footnotes, this was a sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees from the RSU vesting.
After these transactions, he directly held 125,883 shares of common stock and 55,166 RSUs, with the RSUs scheduled to vest in three substantially equal annual installments beginning on February 17, 2026, subject to his continued service with the company.
PRECISION BIOSCIENCES INC General Counsel and Secretary Dario Scimeca reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into 16,667 shares of common stock, increasing his direct holdings. Each RSU represents a right to receive one common share.
On February 18, 2026, he sold 4,925 common shares in an open-market transaction at $3.84 per share under a pre-established Rule 10b5-1 trading plan. The sale was a "sell-to-cover" transaction, with shares sold only to cover tax withholding obligations and related fees from the RSU vesting.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested, each representing one share of common stock, as part of an award scheduled to vest in three equal annual installments beginning on that date.
In connection with this vesting, on February 18, 2026 he executed an open-market sell-to-cover of 4,925 common shares at $3.84 per share under a pre-established Rule 10b5-1 plan, solely to satisfy tax withholding and related fees. After these transactions, he directly held 121,926 common shares and 33,333 RSUs, with an additional 7,931 common shares held indirectly through a charitable remainder unitrust.
DTIL reported Form 144 transactions involving restricted stock vesting and a recent resale. The filing shows 4,925 common shares listed under "Securities To Be Sold" with an event date of 02/17/2026 described as "Restricted Stock Vesting" and labeled "Issuer" and "Compensation". The filing also records that 10,200 common shares were sold by James Jefferson Revocable Trust on 01/21/2026 for $41,073.36.
DTIL reported an insider sale notice for common stock under Form 144. The filing lists 4,925 shares as restricted stock vesting to be sold on 02/17/2026 and shows 8,854 shares sold during the prior three months on 01/21/2026. The broker listed is Fidelity Brokerage Services LLC.